Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis
Objective: To evaluate the survival benefit of metformin use for pancreatic cancer (PC) patients underwent pancreatectomy.Methods: Databases including EMBASE, PubMed, the Cochrane Library were searched to identify studies relevant to the outcomes on the survival benefit of metformin use for the PC p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2020.00282/full |
| _version_ | 1831666128402776064 |
|---|---|
| author | Junqiang Zhang Jichun Ma Lingyun Guo Bo Yuan Zuoyi Jiao Yumin Li |
| author_facet | Junqiang Zhang Jichun Ma Lingyun Guo Bo Yuan Zuoyi Jiao Yumin Li |
| author_sort | Junqiang Zhang |
| collection | DOAJ |
| description | Objective: To evaluate the survival benefit of metformin use for pancreatic cancer (PC) patients underwent pancreatectomy.Methods: Databases including EMBASE, PubMed, the Cochrane Library were searched to identify studies relevant to the outcomes on the survival benefit of metformin use for the PC patients who underwent pancreatectomy until June 30, 2019. STATA 12.0 software was used to performed the meta-analysis.Results: 12 studies involving 35,346 PC patients were included in this meta-analysis. With a random-model, there are significant differences in overall survival (HR = 0.85, 95% CI: 0.77–0.94, P = 0.002) between PC patients who were treated with metformin underwent pancreatectomy and those who underwent pancreatectomy without metformin use. Subgroup analyses showed Caucasians (HR = 0.903, 95% CI = 0.825–0.940, P = 0.008) and Asian (HR = 0.691, 95% CI = 0.588–0.813, P = 0.001) PC patients have a significantly reduced risk of death for metformin users. Subgroup analyses also showed a survival benefit for PC patients at stage I-II (HR = 0.762, 95% CI = 0.677–0.858, P = 0.0001).Conclusions: Metformin use is related to a better survival benefit for PC patients who underwent pancreatectomy, which would be a potential drug for the treatment of PC. |
| first_indexed | 2024-12-19T19:47:21Z |
| format | Article |
| id | doaj.art-e47f5ff8750045c6a11f841d937d6c71 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-19T19:47:21Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-e47f5ff8750045c6a11f841d937d6c712022-12-21T20:08:07ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2020-07-01710.3389/fmed.2020.00282537157Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-AnalysisJunqiang ZhangJichun MaLingyun GuoBo YuanZuoyi JiaoYumin LiObjective: To evaluate the survival benefit of metformin use for pancreatic cancer (PC) patients underwent pancreatectomy.Methods: Databases including EMBASE, PubMed, the Cochrane Library were searched to identify studies relevant to the outcomes on the survival benefit of metformin use for the PC patients who underwent pancreatectomy until June 30, 2019. STATA 12.0 software was used to performed the meta-analysis.Results: 12 studies involving 35,346 PC patients were included in this meta-analysis. With a random-model, there are significant differences in overall survival (HR = 0.85, 95% CI: 0.77–0.94, P = 0.002) between PC patients who were treated with metformin underwent pancreatectomy and those who underwent pancreatectomy without metformin use. Subgroup analyses showed Caucasians (HR = 0.903, 95% CI = 0.825–0.940, P = 0.008) and Asian (HR = 0.691, 95% CI = 0.588–0.813, P = 0.001) PC patients have a significantly reduced risk of death for metformin users. Subgroup analyses also showed a survival benefit for PC patients at stage I-II (HR = 0.762, 95% CI = 0.677–0.858, P = 0.0001).Conclusions: Metformin use is related to a better survival benefit for PC patients who underwent pancreatectomy, which would be a potential drug for the treatment of PC.https://www.frontiersin.org/article/10.3389/fmed.2020.00282/fullpancreatic cancermetforminpancreatectomyoverall survivalmeta-analysis |
| spellingShingle | Junqiang Zhang Jichun Ma Lingyun Guo Bo Yuan Zuoyi Jiao Yumin Li Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis Frontiers in Medicine pancreatic cancer metformin pancreatectomy overall survival meta-analysis |
| title | Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis |
| title_full | Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis |
| title_fullStr | Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis |
| title_full_unstemmed | Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis |
| title_short | Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis |
| title_sort | survival benefit of metformin use for pancreatic cancer patients who underwent pancreatectomy results from a meta analysis |
| topic | pancreatic cancer metformin pancreatectomy overall survival meta-analysis |
| url | https://www.frontiersin.org/article/10.3389/fmed.2020.00282/full |
| work_keys_str_mv | AT junqiangzhang survivalbenefitofmetforminuseforpancreaticcancerpatientswhounderwentpancreatectomyresultsfromametaanalysis AT jichunma survivalbenefitofmetforminuseforpancreaticcancerpatientswhounderwentpancreatectomyresultsfromametaanalysis AT lingyunguo survivalbenefitofmetforminuseforpancreaticcancerpatientswhounderwentpancreatectomyresultsfromametaanalysis AT boyuan survivalbenefitofmetforminuseforpancreaticcancerpatientswhounderwentpancreatectomyresultsfromametaanalysis AT zuoyijiao survivalbenefitofmetforminuseforpancreaticcancerpatientswhounderwentpancreatectomyresultsfromametaanalysis AT yuminli survivalbenefitofmetforminuseforpancreaticcancerpatientswhounderwentpancreatectomyresultsfromametaanalysis |